SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosis

Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20(4):1128–43.

Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K, et al. Body fatness and cancer—viewpoint of the IARC working group. N Engl J Med. 2016;375(8):794–8.

Chlebowski R, Luo J, Anderson G, Simon M, Barrington W, Reding K, et al. Abstract GS5-07: weight change in postmenopausal women and breast cancer risk in the women’s health initiative observational study. Cancer Res. 2018;78(4 suppl):GS5-07–GS5-07.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016;534(7605):47–54.

Tripathy D, Sohn J, Im S‑A, Colleoni M, Franke F, Bardia A, et al. Abstract GS2-05: first-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer. Cancer Res. 2018;78(4 suppl):GS2-05–GS2-05. Results from the randomized phase III MONALEESA-7 trial.

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–48.

Fasching PA, Jerusalem GHM, Pivot X, Martin M, Laurentiis MD, Blackwell KL, et al. Phase III study of ribociclib (LEE011) plus fulvestrant for the treatment of postmenopausal patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2‑negative (HER2–) advanced breast cancer (aBC). J Clin Oncol. 2016;34(15 suppl):TPS624-TPS. who have received no or only one line of prior endocrine treatment (ET): MONALEESA-3.

Singh H, Howie L, Bloomquist E, Wedam S, Amiri-Kordestani L, Tang S, et al. Abstract GS5–06: a U.S. food and drug administration pooled analysis of outcomes of older women with hormone-receptor positive metastatic breast cancer treated with a CDK4/6 inhibitor as initial endocrine based therapy. Cancer Res. 2018;78(4 suppl):GS5-06–GS5-06.

Finn R, Liu Y, Martin M, Rugo H, Dieras V, Im S‑A, et al. Abstract P2-09-10: comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study. Cancer Res. 2018;78(4 suppl):P2-09-10–P2-09-10.

Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.

Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol. 2012;13(7):688–95.

Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T, et al. Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; https://doi.org/10.1093/jnci/dju066 .

Sparano J, O’Neill A, Alpaugh K, Wolff A, Northfelt D, Dang C, et al. Abstract GS6-03: circulating tumor cells (CTcs) five years after diagnosis are prognostic for late recurrence in operable stage II–III breast cancer. Cancer Res. 2018;78(4 suppl):GS6-03–GS6-03.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.

Stover D, Parsons H, Ha G, Freeman S, Barry B, Guo H, et al. Abstract GS3-07: genome-wide copy number analysis of chemotherapy-resistant metastatic triple-negative breast cancer from cell-free DNA. Cancer Res. 2018;78(4 suppl):GS3-07–GS3-07.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–46.

Sestak I, Regan M, Dodson A, Viale G, Thürlimann B, Colleoni M, et al. Abstract GS6-01: integration of clinical variables for the prediction of late distant recurrence in patients with oestrogen receptor positive breast cancer treated with 5 years of endocrine therapy. Cancer Res. 2018;78(4):GS6-01–GS6-01.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thurlimann B, et al. Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol. 2018; https://doi.org/10.1200/jco.2017.76.4258 .

Dubsky P, Fesl C, Singer C, Pfeiler G, Kronenwett R, Hubalek M, et al. Abstract GS6-04: the EndoPredict score predicts residual cancer burden after neoadjuvant chemotherapy and after neoendocrince therapy in HR+/HER2- breast cancer patients from ABCSG 34. Cancer Res. 2018;78(4 suppl):GS6-04–GS6-04.

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–22.